Latest news for Iris Acquisition (NASDAQ:IRAAW) Stock

Iris Acquisition Corp is a blank check company.

Iris Acquisition Corp

Benchmark analyst Mark Zgutowicz reiterates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Buy and maintains $150 price target.

News

Price Target

Reiteration

Analyst Ratings

DASH

Benchmark Reiterates Buy on DoorDash, Maintains $150 Price Target

SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the cerebral spinal fluid (CSF) of Alzheimer's patients; an important finding since increased α-syn has been correlated with worse cognitive performance and is not a target for any currently approved Alzheimer's treatments &nbsp;
SNK01 treatment appears to stabilize or improve cognitive function and reduce α-synuclein levels in CSF in addition to improving previously reported amyloid, tau, and neuroinflammatory markers (GFAP, NfL, YKL-40) in the majority of patients
SANTA ANA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the presentation of a poster entitled, "Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function." SNK01 is a first-in-kind, autologous non-genetically modified NK cell product with significantly increased cytotoxicity and over 90% activating receptor expression that can be consistently produced from any donor. Clinical trial data on the effect of SNK01 α-synuclein and cognitive assessments in patients with Alzheimer's Disease ("AD") was presented at the 2024 Alzheimer's Association International Conference ("AAIC") held in Philadelphia, PA on July 30, 2024.

Biotech

General

NKGN

NKGen Biotech Presents New SNK01 Biomarker Data At The 2024 AAIC Held On July 30, 2024

Easy Installation And Significant Performance Enhancements

COMM

CommScope Launches STARLINE 1.8 GHz ESD Amplifiers For DOCSIS 3.1 Networks; Provides Upgrade Path To DOCSIS 4.0

NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.64 by 6.25 percent. The company reported quarterly sales of $64.200 million which missed the analyst consensus estimate of $64.750 million by 0.85 percent. This is a 7.76 percent decrease over sales of $69.600 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

NXRT

NexPoint Residential Q2 2024 FFO $0.68 Beats $0.64 Estimate, Sales $64.200M Miss $64.750M Estimate

Truist Securities analyst Michael Lewis maintains Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) with a Buy and raises the price target from $29 to $33.

Truist Securities Maintains Buy on Highwoods Props, Raises Price Target to $33

In the picturesque town of Seeley Lake, Montana, surrounded by beautiful forests, Pyramid Mountain Lumber has been the heartbeat of the community for 75 years. But now, despite abundant wood, the mill is closing its doors for the most surprising reason: the town lacks a centralized sewer system.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
</ul>
Pyramid Mountain Lumber, the town's biggest employer, has been a family-owned business since 1948. Todd Johnson, whose grandfather started the mill, has worked there his entire life. &#8220;I&#8217;ve never drawn a paycheck from any other business in my whole life. I started here in sixth grade,&#8221; Johnson shared. &#8220;This is all I&#8217;ve ever known.&#8221;
The closure is not due to political battles or environmental issues. Instead, it's because the town doesn&#8217;t have a centralized sewer system, which prevents new affordable housing from being built. This makes it difficult to attract and retain workers.&nbsp;
Johnson explains, &#8220;There hasn&#8217;t been an apartment, duplex, or fourplex built in this town in over 30 years, so … when you&#8217;re talking about entry-level housing for more blue-collar workers, there&#8217;s just none available.&#8221;
Trending: Finally allowing commercial real estate investing to be more accessible —<a href="https://www.benzinga.com/money/equitymultiple-ascent-fund"> This fund aims to triple your money in 10 years is with a surprisingly low minimum.</a>
Missoula County officials explain that developers can&#8217;t build cost-effective housing for the mill's blue-collar workers without a sewer system. High-end septic systems are too expensive for the kind of housing needed in Seeley Lake. The town has debated installing a sewer system for years, but residents have consistently voted against it due to concerns about costs and changing the town&#8217;s character.
The impact of this decision is now hitting home. Pyramid Mountain Lumber, which cuts various sizes of lumber and has grown significantly over the decades, cannot find enough workers to keep running. &#8220;To make the announcement to the crew was probably the toughest thing,&#8221; Johnson told ABC News. &#8220;I&#8217;ve got friends, family, generations of good friends that work here. I had to tell them we&#8217;re going to shut the doors.&#8221;
The shortage of workers isn't just affecting the mill. Kyle Marx, the general manager of Rovero's Hardware, mentioned they&#8217;re &#8220;running on a skeleton crew&#8221; during their busiest season. &#8220;No affordable housing here,&#8221; Marx said. &#8220;Rentals have diminished since COVID hit, and everybody came up here, bought every rental that was available, and turned them into vacation rentals or moved up here themselves.&#8221;
See Also: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
Dee Baker, who owns the Grizzly Claw Trading Company, said this has been a problem for years. "There could be low-income housing built, but the people in the town cannot come to an agreement with Missoula County," she said.
Dave Strohmaier, chair of the Missoula Board of County Commissioners, explained the irony of the situation. &#8220;The lack of infrastructure is a big reason why Pyramid Mountain Lumber cannot find housing for their employees, and hence, change is upon us,&#8221; he said.
With the mill's payroll contributing over $6 million a year to the local economy, its closure will change the fabric of Seeley Lake. &#8220;You take that out of this economy, it&#8217;ll change the fabric of the town. There&#8217;s no doubt,&#8221; Johnson noted.
Although surrounded by abundant natural resources, Seeley Lake faces a future where its long-standing timber industry might disappear, all because there isn't a place for workers to live.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that lets you seize the private credit boom.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Real Estate

Although There's An Abundance Of Wood, This 75-Year-Old Mill In Montana Is Closing For The Most Surprising Reason

aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim's research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).

ATYR

aTyr Pharma Announces Research Study with Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme

Truist Securities analyst Anthony Hau maintains Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Hold and raises the price target from $65 to $70.

Truist Securities Maintains Hold on Equity Lifestyle Props, Raises Price Target to $70

WIIM

HEES

H&E Equipment Services shares are trading lower after the company reported worse-than-expected Q2 financial results.

<ul>
<li>Launching into this growth market1 as part of the company's geographic expansion strategy</li>
<li>Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evolus.com%2F&amp;esheet=54099911&amp;newsitemid=20240730657453&amp;lan=en-US&amp;anchor=Evolus%2C+Inc.&amp;index=1&amp;md5=1f4593444d661564b0233037f1f5dd5a">Evolus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva&#xAE; (prabotulinumtoxinA).
Nuceiva&#xAE; is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2.

Global

EOLS

Evolus Expands Global Footprint With Introduction Of Nuceiva In Australia

Truist Securities analyst Anthony Hau maintains Alpine Income Prop Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Hold and raises the price target from $16 to $18.

PINE

Truist Securities Maintains Hold on Alpine Income Prop Trust, Raises Price Target to $18

Charles River Laboratories Partners With FOXG1 Research Foundation To Advance AAV9 Gene Therapy Clinical Trials; Collaboration Leverages Plasmid And Viral Vector CDMO Expertise To Drive Drug Development For FOXG1 Syndrome And Related Neurological Disorders

Barclays analyst Saket Kalia maintains Varonis Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) with a Overweight and raises the price target from $55 to $60.

VRNS

Barclays Maintains Overweight on Varonis Systems, Raises Price Target to $60

NUBURU, Inc. ("NUBURU" or the "Company") (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BURU#OTC">BURU</a>), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced that, on July 29, 2024, it received a notification from NYSE American LLC ("NYSE American") informing Nuburu that it has resolved the continued listing deficiency with respect to low selling price as described in Section 1003(f)(v) of the NYSE American Company Guide. As a result, the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension on Nuburu's common stock on NYSE American. The common stock will commence trading on NYSE American on Friday, August 2, 2024 under the symbol "BURU" and CUSIP "67021W301".

BURU

NUBURU Announces Removal Of Trading Suspension; Will Commence Trading On NYSE American On Friday, August 2, 2024 Under The Symbol "BURU"

JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) stock gained after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/b40031524/jetblue-announces-second-quarter-2024-results" rel="noreferrer noopener">better-than-expected second-quarter 2024 results</a>.
The air carrier reported a second-quarter adjusted EPS of $0.08, above the consensus loss of $0.13, and <a href="https://www.benzinga.com/earnings">compared to EPS of $0.45 reported a year ago.</a>
JetBlue reported operating revenue of $2.428 billion, down 6.9% year over year, beating the consensus of $2.397 billion. Second quarter system capacity decreased by 2.7% year over year.
&#8220;In the second quarter, we continued to implement our JetForward strategy with the announcement of more significant network changes&#8230; As we progress through the second half of the year, we&#8217;ll be announcing additional initiatives designed to further enhance our customer value proposition, close the gap in our product offering to our peers, and drive significant financial benefit,&#8221; commented Marty St. George, JetBlue&#8217;sJetBlue&#8217;s president.
The operating margin for the quarter declined 670 bps to 2.3%, and the adjusted operating margin stood at 2.4%, down YoY from 9.9%.
Operating expenses for the quarter declined slightly by 0.1% to $2.37 billion, while the operating expenses per available seat mile (CASM) rose 2.6% YoY.
Adjusted operating expenses rose 0.9% to $1.73 billion. Operating expenses per available seat mile, excluding fuel and other non-airline operating expenses, increased by 3.7% YoY.
JBLU&#8217;s Average fuel price in the second quarter was $2.87 per gallon, up from $2.73 a year ago.
The airline ended the quarter with ~$1.6 billion in liquidity, excluding an undrawn $600 million revolving credit facility.
JBLU delivered improved operational performance year-over-year with a completion factor of 98.8%, up from 97.8% YoY.
&#8220;While many of these underlying initiatives will take time to ramp to their full potential, with the strong foundation of JetForward, we are poised to generate $800 &#8211; $900 million of incremental EBIT from 2025 through 2027 and expect the benefit to be realized evenly over those three years,&#8221; said Ursula Hurley, JetBlue&#8217;s chief financial officer.
&#8220;We are setting ourselves on a path to restore our balance sheet health, and in support of securing our financial future, we are announcing an incremental aircraft deferral of approximately $3 billion of planned capital expenditures. Our focus will be on driving value from our existing asset base and, ultimately, generating positive free cash flow,&#8221; Hurley added.
Q3 Guidance: JetBlue anticipates a year-over-year revenue drop of 5.5% to 1.5%; <a href="https://www.benzinga.com/calendars/guidance">Available Seat Miles (ASMs) are expected to decrease by 6% to 3% YoY.</a>
CASM ex-fuel is projected to rise 6% to 8%, and the expected fuel price per gallon is between $2.82 and $2.97.
2024 Guidance: JetBlue anticipates a year-over-year revenue drop of 6% to 4% (prior view: Down low single digits); Available Seat Miles (ASMs) are expected to decrease by 5% to 2.5% YoY (prior view: Down low single digits).
2024 CASM ex-fuel is expected to increase 6.5% to 8.5%; the projected fuel price per gallon is between $2.80 and $3.00.
Price Action: JBLU shares are trading higher by 4.22% to $6.18 premarket at the last check Tuesday.
Photo via Wikimedia Commons

Guidance

JBLU

JetBlue Q2 Earnings: Revenue And EPS Beat, Unveils JetForward Strategy, Targets $800M-$900M Incremental EBIT By 2027

GRUBBRR Partners With Olo To Streamline Restaurant Operations With Integrated Self-Ordering And Payment Solutions; Combines Self-Ordering Kiosks And Digital Menu Boards With Olo's Ordering And Payment Processing Capabilities

SCOR

Comscore Announces Comprehensive Measurement Of YouTube Audiences Across All Digital Devices In The US

Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) will release its fiscal year fourth quarter financial results, after the <a href="https://www.benzinga.com/quote/MSFT/earnings">closing bell on Tuesday.</a>
Analysts expect the Redmond, Washington-based company to report quarterly earnings at $2.93 per share, up from $2.69 per share in the year-ago period. Microsoft is seen posting revenue of $64.39 billion, compared to $56.19 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 23, <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beeab/brent-bracelin">Piper Sandler analyst Brent Bracelin</a> reiterated Microsoft with an Overweight rating, while increasing the price target from $465 to $485.
With the recent buzz around Microsoft, some investors may be eyeing potential gains from the company's dividends too. As of now, Microsoft offers an annual dividend yield of 0.70%, which is a quarterly dividend amount of 75 cents per share ($3.00 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $853,460 or around 2,000 shares. For a more modest $100 per month or $1,200 per year, you would need $170,692 or around 400 shares.
Read This: <a href="https://www.benzinga.com/news/24/07/40009802/top-5-financials-stocks-that-may-fall-off-a-cliff-this-month">Top 5 Financials Stocks That May Fall Off A Cliff This Month</a>
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($3.00 in this case). So, $6,000 / $3.00 = 2,000 ($500 per month), and $1,200 / $3.00 = 400 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
MSFT Price Action: Shares of Microsoft rose 0.3% to close at $426.73 on Monday.
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40007546/anixa-biosciences-and-3-other-stocks-under-5-insiders-are-buying">Anixa Biosciences And 3 Other Stocks Under $5 Insiders Are Buying</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: Shutterstock

Long Ideas

Markets

Trading Ideas

MSFT

How To Earn $500 A Month From Microsoft Stock Ahead Of Q4 Earnings

180 Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) ("180 Life Sciences" or the "Company"), today announced topline results from a clinical pharmacology study (the "Study"), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic (PK) profile of a generic approved CBD product, Epidiolex&#xAE;, with two solid formulations. We believe this type of trial has yet to be examined in a clinical setting. For the Company's trial, twelve volunteers received all three formulations in a crossover randomized trial. &nbsp;
Epidiolex is a CBD dissolved in 8% ethanol and 80% sesame seed oil, plus flavoring agents, that is given as a liquid solution via syringe in the mouth. Results of the clinical trial indicate that one of the two solid forms was absorbed faster and exhibited higher maximal levels compared to Epidiolex. Both of the solid formulations were well tolerated.
CBD is a purified product that is not psychoactive, which we believe has potential benefits for treatment of inflammatory processes and pain. A major problem in working with CBD is its low, unpredictable and variable uptake following the most convenient delivery form, by mouth, as a liquid CBD in oil like the approved pharmaceutical Epidiolex, given for epilepsy.

ATNF

180 Life Sciences Reports Positive Topline Results Of A Clinical Pharmacology Study Testing A New Solid Formulation Of CBD With Enhanced Oral Uptake; Twelve Volunteers Received All Three Formulations In A Crossover Randomized Trial

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Iris Acquisition

News

Latest news for Iris Acquisition (NASDAQ:IRAAW) Stock